drugset / Trial / NCT00006066
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
Phase 1
Completed
92 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
Treatment
Summary
The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children. IL-2 is an important substance produced by the body's white blood cells that helps the body fight infection. People with HIV infection do not produce enough IL-2. It is hoped that IL-2 treatment will help boost the immune system in people with HIV infection. It has not been studied very much in children and doctors need to know what doses are safe to give.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed | Vaccine | — | — |
| Subject | Diphtheria and Tetanus Toxoids Adsorbed | Vaccine | — | — |
| Subject | Tetanus and Diphtheria Toxoids Adsorbed | Vaccine | — | — |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |